!!better!! | Kbi-092

The development of KBI-092 involves high-level collaboration within the biopharmaceutical ecosystem. , a leading global Contract Development and Manufacturing Organization (CDMO) , is frequently involved in scaling the production of complex biologics and small molecules for clinical trials.

This open-label study is designed to assess the safety, tolerability, and pharmacokinetics of the drug. It typically begins with a dose of 30 mg twice daily (BID), escalating up to 200 mg BID to determine the Recommended Phase 2 Dose (RP2D). KBI-092

Unlike traditional therapies that target a single pathway, KBI-092 is engineered for a "two-pronged" attack on leukemia cells. Its therapeutic efficacy stems from the selective inhibition of two critical proteins: It typically begins with a dose of 30

Developed primarily by , KBI-092 (HPB-092) is a novel dual-kinase inhibitor designed to disrupt survival signals that allow cancer cells to resist standard treatments. The Mechanism of Action: Dual Inhibition The Mechanism of Action: Dual Inhibition